More observational data show that two common antihypertensive medication classes do not increase COVID-19 infectivity or severity.
Notice of retraction: The first article summarized here, Mehra MR et al. Cardiovascular disease, drug therapy, and mortality in Covid-19, published in the New England Journal of Medicine, has been retracted by the authors after all of the authors were unable to validate the primary data sources. The authors' retraction can be seen here: https://www.nejm.org/doi/full/10.1056/NEJMc2021225.
The relationship between cardiovascular disease (CVD), CV treatment, and the risk for adverse outcomes in patients with COVID-19 has been receiving much attention. Three other research groups now provide more insights.
To investigate CVD as a risk factor for patients with COVID-19 and the association between CVD pharmacotherapy and COVID-19 outcomes, Mehr…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association